The human papilloma virus (HPV) family of DNA tumor viruses includes HPV-16 and HPV-18, which are associated with a large proportion of cervical cancer cases, and HPV-1, which is associated with benign cutaneous warts. HPV late protein L1 is the major capsid protein.
| Inventor | Institute |
|---|---|
| Lawrence Banks | University of Cambridge |
| Cat. #: | 151084 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Cancer types: | Gynaecologic cancer |
| Research Fields: | Cancer;Microbiology |
| Application: | ELISA ; IHC ; IP ; WB |
| Target: | Human papilloma virus type 16, major capsid protein L1 (HPV16 L1) |
| Reactivity: | Human papilloma virus |
| Clone: | CamVir 1 |
| Host: | Mouse |
| Class: | Monoclonal |
| Product description: | The human papilloma virus (HPV) family of DNA tumor viruses includes HPV-16 and HPV-18, which are associated with a large proportion of cervical cancer cases, and HPV-1, which is associated with benign cutaneous warts. HPV late protein L1 is the major capsid protein. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG2a |
| Molecular weight: | 56 kDa |
| Immunogen: | A b galactosidase-L1 fusion protein purified by PAGE. |
| Myeloma used: | NS0 |
| Target background: | The human papilloma virus (HPV) family of DNA tumor viruses includes HPV-16 and HPV-18, which are associated with a large proportion of cervical cancer cases, and HPV-1, which is associated with benign cutaneous warts. HPV late protein L1 is the major capsid protein. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | '-15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Day et al. 2012. Clin Vaccine Immunol. 19(7):1075-82. PMID: 22593236. A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies. Steele et al. 2005. Br J Cancer. 93(2):248-59. PMID: 15986031. T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia. Zhang et al. 1998. Virology. 243(2):423-31. PMID: 9568041. Expression of human papillomavirus type 16 L1 protein in Escherichia coli: denaturation, renaturation, and self-assembly of virus-like particles in vitro. McLean et al. 1990. J Clin Pathol. 43(6):488-92. PMID: 2166093. Production and characterisation of a monoclonal antibody to human papillomavirus type 16 using recombinant vaccinia virus. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151017 | Anti-MBP [R29.6] |
Key Info
Anti-MBP [R29.6]
|
View Tool | |||||||||||||||||||
| 151021 | Anti-CyclinB1 [V152] |
Key Info
Anti-CyclinB1 [V152]
|
View Tool | |||||||||||||||||||
| 151025 | Anti-Vascular endothelium [10] |
Key Info
Anti-Vascular endothelium [10]
|
View Tool | |||||||||||||||||||
| 151026 | Anti-FCGR1 [10.1] mAb |
Key Info
Anti-FCGR1 [10.1] mAb
|
View Tool | |||||||||||||||||||
| 151034 | Anti-HSVUL42 [13D11] |
Key Info
Anti-HSVUL42 [13D11]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.